By: John Ward and Paul Hamill

The pharmaceutical industry has spent decades refining drug discovery, biologics manufacturing and fill-finish operations. However, for many combination products today, the greatest risk to launch timelines no longer sits upstream in formulation or production. Increasingly, the critical path lies in final assembly, packaging, labelling, sterilization management and market release preparation.

This shift is being driven by several converging trends: the rise of complex drug-device combination products, the expansion of personalized and home-based therapies, growing regulatory variation across regions and pressure to rapidly launch products into multiple markets at varying scales. At the same time, the surge in biologics, biosimilars and GLP-1 therapies has intensified competition for manufacturing capacity, particularly for low- and mid-volume projects that larger contractors often deprioritize.

As a result, pharmaceutical companies are being forced to rethink the role of post-fill-finish operations. What was once viewed as a relatively straightforward operational step has become a specialized, highly strategic phase that can determine whether a product launches on time or misses a critical commercial window altogether. Increasingly, success depends not only on technical execution, but also on the flexibility and agility of downstream partners to adapt to compressed timelines, regional variations, changing regulatory requirements and low- to mid-volume production demands.

The Compression Problem

One of the defining challenges in drug-device commercialization is the accumulation of delays throughout development. Clinical timelines move, device decisions evolve, regulatory requirements change and formulation programs shift priorities. By the time a therapy reaches late-stage development, the commercialization window is often compressed significantly.

This is especially true for combination products. In many cases, the delivery method is not fully finalized during early clinical development. Products may initially be developed in vial presentation before transitioning later to prefilled syringes, autoinjectors, wearable injectors or more customized delivery systems. That evolution introduces substantial late-stage complexity at precisely the point where launch timelines become least flexible.

Pharmaceutical companies often begin engaging assembly and packaging partners only in late-stage Phase 3 development. For biosimilars, timelines can be even tighter, sometimes shrinking to less than six months before anticipated launch. At that stage, companies must still finalize device selection, market-specific packaging, labelling strategies, serialization requirements, assembly tooling, regulatory approvals and release preparation. Even when using established device platforms, adaptation work is rarely eliminated entirely, as regional variations or packaging requirements can still require customized tooling and validation.

The result is that late-stage operations become the bottleneck through which every other upstream success must pass. This means that even if clinical development, manufacturing and fill-finish activities are completed successfully, delays in assembly, packaging, labelling or release preparation can still push back launch timelines and ultimately delay patient access to the product.

Delivery Devices are Increasingly Driving Late-Stage Complexity

Traditional injectable launches using vial formats remain comparatively straightforward from a final-stage perspective. However, as more therapies move toward patient-centric delivery formats such as prefilled syringes, autoinjectors and wearable systems, the complexity of downstream operations increases significantly.

Final assembly now requires manufacturers to manage a combination of technical, regulatory and operational demands, including:

• Device-container compatibility
• Assembly tooling and automation
• Verification and functional testing
• Human factors and patient usability
• Sterility assurance and validation
• Serialization and traceability
• Regional packaging and labelling variations
• Small batch manufacturing requirements
• Multiple stock-keeping unit (SKU) configurations and rapid changeovers

Importantly, a low-volume orphan drug or personalized biologic must meet the same quality and regulatory standards as a blockbuster therapy. This creates a significant challenge for manufacturers optimized primarily for large-volume production. Many high-throughput operations are designed around scale efficiency rather than the flexibility increasingly required for specialized or regionally targeted launches.

The rapid growth of GLP-1 therapies and biologics has intensified this pressure across both in-house and outsourced manufacturing networks. Larger contract manufacturers are naturally prioritizing high-volume programs, leaving many lower-volume or more specialized projects competing for limited late-stage capacity.

Why Europe Changes the Equation

The challenge becomes even more pronounced when launching products internationally. The US market, while highly regulated, generally allows for larger, more standardized packaging runs with fewer language variations.

Europe introduces a completely different operational dynamic. A single European launch may require packaging, instructions for use, labels and artwork variations across more than 20 individual markets. Batch sizes that appear commercially significant in aggregate quickly fragment into much smaller country-specific volumes. A production run of 100,000 units in the US may translate into dozens of smaller European batches once distributed across national markets, languages and regulatory requirements. That fragmentation creates operational complexity throughout assembly and packaging workflows.

Moreover, regulatory and artwork changes occur frequently. Even relatively minor changes to wording or compliance information can trigger packaging updates across multiple countries simultaneously. Managing those revisions manually through traditional email-driven approval systems creates substantial risk for errors, delays or version-control failures.

As combination products become more globally distributed, pharmaceutical companies increasingly require digitally integrated quality and artwork management systems capable of handling high-mix, low-volume manufacturing environments with full traceability. This is one reason why localized late-stage strategies are gaining importance. Rather than relying solely on centralized manufacturing models, companies are increasingly evaluating how final assembly and packaging can occur closer to regional end markets.

The Growing Importance of Localized Market Entry

In the past, pharmaceutical supply chains were built around centralization and economies of scale. Today, flexibility is becoming equally important. Rather than relying entirely on centralized manufacturing models, companies are increasingly evaluating how final assembly and packaging can occur closer to the destination market.

A more localized strategy can help companies:

• Respond more effectively to regional regulatory and packaging requirements
  Localized assembly and packaging operations make it easier to manage country-specific labeling, language variations, artwork updates and serialization requirements without disrupting larger global supply chains. This is particularly important in Europe, where a single product launch may require multiple packaging versions across different markets.
• Reduce commercial risk associated with logistics delays and shelf-life loss
  Even with robust cold-chain infrastructure, international shipping delays, customs bottlenecks or documentation issues can significantly shorten the usable shelf life of sensitive therapies. Performing final assembly and packaging closer to the destination market helps preserve product viability and supports faster market release.
• Support smaller, more flexible market-entry strategies
  As therapies become increasingly personalized and targeted, pharmaceutical companies are moving away from large uniform launches toward smaller, phased or region-specific rollouts. Localized late-stage operations provide the agility needed to support low- and mid-volume batch sizes, faster changeovers and evolving demand patterns.

This issue becomes more acute for therapies distributed across multiple regions with varying regulatory processes. Even movement between European jurisdictions can introduce delays depending on customs procedures or documentation requirements.

At the same time, localized strategies support the broader industry movement toward personalized medicine and decentralized care delivery. More therapies are now designed for self-administration outside traditional hospital environments, increasing demand for patient-ready kits, customized packaging configurations and region-specific instructions. The late-stage supply chain, once responsible for simply shipping a product, is increasingly delivering a complete patient-use system.

Sterilization and Hidden Risks

One of the most underestimated aspects of commercialization is sterilization management. For certain applications, particularly ophthalmic and other highly sensitive drug-device products, terminal sterilization introduces additional validation, compatibility and shelf-life considerations that many pharmaceutical organizations encounter only infrequently.

Sterilization validation alone can add several months to development timelines, depending on the product, delivery system and required shelf-life studies. Different sterilization methods may also interact differently with device materials, packaging configurations or drug stability profiles.

These considerations often emerge late in development, particularly for companies with limited prior experience in device-oriented manufacturing or terminal sterilization processes. The risk is that they are discovered too late to avoid launch disruption. To reduce this risk, organizations need to involve late-stage assembly, packaging and sterilization specialists earlier in the development process so that validation requirements, material compatibility, regulatory considerations and shelf-life implications can be assessed well before commercial timelines become compressed.

A Strategic Shift in Pharmaceutical Commercialization

As late-stage operations become more complex, assembly and packaging are evolving from operational functions into critical components of launch strategy. Pharmaceutical companies are increasingly seeking partners that can support smaller batch sizes, regional customization and accelerated timelines without compromising quality or compliance.

Success now depends on more than manufacturing capacity alone. Integrated quality systems, digital traceability, automated assembly technologies and expertise in sterilization and release preparation are becoming essential to managing the growing complexity of downstream commercialization. At the same time, the continued growth of biologics, biosimilars, personalized medicines and home-based therapies is increasing demand for more specialized delivery systems and agile market-entry models.

As a result, companies that continue to treat post-fill-finish activities as a secondary consideration risk underestimating one of the most critical stages of commercialization. By contrast, organizations that engage downstream partners earlier in development are better positioned to manage regional requirements, reduce commercial risk and maintain launch timelines.

In an increasingly competitive and fast-moving pharmaceutical market, the ability to execute final assembly and packaging efficiently and flexibly is becoming a defining factor in how quickly therapies reach patients.

About the Authors